CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

Mark H. O'Hara, Eileen M. O'Reilly, Gauri Varadhachary, Robert A. Wolff, Zev A. Wainberg, Andrew H. Ko, George Fisher, Osama Rahma, Jaclyn P. Lyman, Christopher R. Cabanski, Rosemarie Mick, Pier Federico Gherardini, Lacey J. Kitch, Jingying Xu, Theresa Samuel, Joyson Karakunnel, Justin Fairchild, Samantha Bucktrout, Theresa M. LaVallee, Cheryl SelinskyJacob E. Till, Erica L. Carpenter, Cécile Alanio, Katelyn T. Byrne, Richard O. Chen, Ovid C. Trifan, Ute Dugan, Christine Horak, Vanessa M. Hubbard-Lucey, E. John Wherry, Ramy Ibrahim, Robert H. Vonderheide

Research output: Contribution to journal › Article › peer-review

159 Scopus citations

Fingerprint

Dive into the research topics of 'CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study'. Together they form a unique fingerprint.

Medicine & Life Sciences